All News
Rituximab Induction and Maintenance in Older ANCA–Associated Vasculitis Patients
A cohort study suggests that rituximab (RTX) use among patients 75 years and older with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is efficacious but also has a high risk of serious adverse events, likely related to associated steroid use and the advanced age of the po
Read Article
ICYMI: 2021 Rheumatology Year in Review
For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
What Happened to Kawasaki Disease During COVID-19?
During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD cases fell and remained low during the period of masking and school closure.
Read Article
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/IoWISgL3SY https://t.co/JV1Yv5Pg9d https://t.co/b8UoQ4zMUV https://t.co/VwNgVQ5End
Dr. John Cush RheumNow ( View Tweet)
RTX Induction and Maintenance in Older ANCA–Associated Vasculitis Patients
A cohort study suggests that RTX use among patients 75 years and older with ANCA–associated vasculitis (AAV) is efficacious but also has a high risk of serious adverse events.
https://t.co/HF9hyQcHZV https://t.co/xpDSohFcRK
Links:
Dr. John Cush RheumNow ( View Tweet)
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
@Janetbirdope
Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/DyVCxDVPE7 https://t.co/PF7zqxX7yk
Links:
Dr. John Cush RheumNow ( View Tweet)
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/NEZDB20OXN https://t.co/4123Gh2v2Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/oa619uNgnB https://t.co/gyNnsMDXGo
Links:
Dr. John Cush RheumNow ( View Tweet)
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
Links:
Dr. John Cush RheumNow ( View Tweet)
506 ANCA-Assoc vasculitis pt study - 72% were MPO-ANCA+ & 68% w/ renal Dz, & Rx w/ RTX (59%) or CTX (33%) - 16% died, 10% ESRD & 13% relapsed. ANCA negativity had less relapse (HR 0.55; 0.38, 0.81) but not less ESRD or death @ 5 yrs https://t.co/iCrxH9UArl https://t.co/6s3TmQqxVQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG
Links:
Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Vessels Glowing in the Dark - Does it Matter?
https://t.co/ZM6kmqM9Ap https://t.co/ibqwrE3p1g
Links:
Dr. John Cush RheumNow ( View Tweet)
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/AVQ7lRYoRw
Links:
Dr. John Cush RheumNow ( View Tweet)
#good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a receptor blocker - maintains more remission and less relapses and less total prednisone OP0180 @eular_org #EULAR2022 @RheumNow Bad news $$💰 will limit access.
Janet Pope Janetbirdope ( View Tweet)
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
Janet Pope Janetbirdope ( View Tweet)
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
Janet Pope Janetbirdope ( View Tweet)
Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i
Janet Pope Janetbirdope ( View Tweet)
